Advanced search
Publication Cover
Current Medical Research and Opinion Volume 31, 2015 - Issue 2
Submit an article Journal homepage
730
Views
18
CrossRef citations to date
0
Altmetric
Original article

Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs

Melea A. WardUniversity of North Carolina, Department of Pharmaceutical Outcomes and Policy, Chapel Hill, NC, USACorrespondence[email protected]
,
Gang FangUniversity of North Carolina, Department of Pharmaceutical Outcomes and Policy, Chapel Hill, NC, USA
,
Kristy L. RichardsLineberger Comprehensive Cancer Center, Division of Hematology/Oncology, Chapel Hill, NC, USA
,
Christine M. WalkoUniversity of North Carolina, Department of Pharmacotherapy and Experimental Therapeutics, Chapel Hill, NC, USA;DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
,
Stephanie R. EarnshawRTI Health Solutions, RTI International, Research Triangle Park, NC, USA
,
Laura E. HappeHumana Inc., Louisville, KY, USA
&
Susan J. BlalockUniversity of North Carolina, Department of Pharmaceutical Outcomes and Policy, Chapel Hill, NC, USA
 show all
Pages 289-297 | Accepted 11 Nov 2014, Published online: 10 Dec 2014

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Lisa J. McGarry, Yaozhu J. Chen, Victoria Divino, Shibani Pokras, Catherine R. Taylor, Julie Munakata, Christopher C. Nieset, Hui Huang, Elias Jabbour & Daniel C. Malone. (2016) Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. Current Medical Research and Opinion 32:2, pages 289-299.
Read now

Articles from other publishers (17)

Samantha E. Clark, Zachary A. Marcum, Jerry Radich, Ruth Etzioni & Anirban Basu. (2023) Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients. Journal of Oncology Pharmacy Practice.
Crossref
Justin Gatwood, Ankur Dashputre, Abhijeet Rajpurohit, Katie Gatwood, Emily Mackler, Leah Wallace, Karen Farris, Amna Rizvi-Toner & Joel Farley. (2023) Impact of initiating oral anticancer agents for leukemia on adherence to medications for multiple chronic conditions. Journal of Oncology Pharmacy Practice, pages 107815522311719.
Crossref
Karen B. Farris, Tiffany Cadwallader, Joel Farley, Katie Gatwood, Emily Mackler & Justin Gatwood. (2022) Implementation of a model integrating primary and oncology pharmacists' care for patients taking oral anticancer agents (OAA). Exploratory Research in Clinical and Social Pharmacy 7, pages 100163.
Crossref
Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin, Eric Q. Wu & Pallavi Patwardhan. (2022) Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States. Journal of Health Economics and Outcomes Research 9:2.
Crossref
Ehab Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin, Eric Wu & Pallavi Patwardhan. (2022) Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States. Journal of Health Economics and Outcomes Research 9:2, pages 19-29.
Crossref
Carla Boquimpani, Fernanda Salles Seguro, Gustavo Henrique Romani Magalhães, Ingrid Luise Soares Pinto, Israel Bendit, Jaisson André Pagnoncelli Bortolini, Katia Borgia Barbosa Pagnano, Renato Centrone & Vaneuza Funke. (2022) Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice. Hematology, Transfusion and Cell Therapy 44:3, pages 402-409.
Crossref
Jennifer J. Wilkes, Gary H. Lyman, David R. Doody, Shasank Chennupati, Laura K. Becker, Pamela E. Morin, Lena E. Winestone, Henry J. Henk & Eric J. Chow. (2021) Health Care Cost Associated With Contemporary Chronic Myelogenous Leukemia Therapy Compared With That of Other Hematologic Malignancies. JCO Oncology Practice 17:3, pages e406-e415.
Crossref
Christel C. L. M. Boons, Lonneke Timmers, Jeroen J. W. M. Janssen, Peter E. Westerweel, Nicole M. A. Blijlevens, Willem M. Smit, Imke H. Bartelink, Janneke A. Wilschut, Eleonora L. Swart, N. Harry Hendrikse & Jacqueline G. Hugtenburg. (2020) Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib. European Journal of Clinical Pharmacology 76:9, pages 1213-1226.
Crossref
Hsiao Ling Phuar, Charles E. Begley, Wenyaw Chan & Trudy Millard Krause. (2020) Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia. American Journal of Clinical Oncology 43:7, pages 517-525.
Crossref
Ankur A. Dashputre, Katie S. Gatwood & Justin Gatwood. (2020) Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Journal of Managed Care & Specialty Pharmacy 26:2, pages 186-196.
Crossref
Yasuhiro Maeda, Atsushi Okamoto, Kenta Yamamoto, Go Eguchi & Yoshitaka Kanai. (2019) Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic Phase. Reports 2:4, pages 25.
Crossref
Hsiao Ling PhuarCharles E. BegleyWenyaw ChanTrudy Millard Krause. (2019) Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study. Journal of Managed Care & Specialty Pharmacy 25:10, pages 1140-1150.
Crossref
Alan Rodrigues Andrade, Daniel da Silva Leitão, Igor Penha Paz, Talitta Ribeiro Evangelista, Vanessa Joia de Mello & Moisés Hamoy. (2019) Analysis of imatinib adherence in chronic myeloid leukemia: a retrospective study in a referral hospital in the Brazilian Amazon. Hematology, Transfusion and Cell Therapy 41:2, pages 106-113.
Crossref
Michael Mounié, Nadège Costa, Martin Gauthier, Aurore Palmaro, Cyrille Delpierre, Fabien Despas, Maryse Lapeyre Mestre, Guy Laurent, Nicolas Savy & Laurent Molinier. (2018) Évaluation du coût de la prise en charge des patients atteints de Leucémie Myéloïde Chronique (LMC) en Midi-Pyrénées : impact économique des différents Inhibiteurs de Protéines Kinases. Journal de gestion et d'économie médicales Vol. 36:2, pages 109-122.
Crossref
Yasuhiro Maeda, Atsushi Okamoto, Shin-ichiro Kawaguchi, Akiko Konishi, Kenta Yamamoto, Go Eguchi, Yoshitaka Kanai & Terufumi Yamaguchi. (2017) Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors. Acta Haematologica 138:3, pages 140-142.
Crossref
Massimo Breccia, Guendalina Graffigna, Sara Galimberti, Alessandra Iurlo, Ester Pungolino, Michele Pizzuti, Alessandro Maggi, Franca Falzetti, Silvana Franca Capalbo, Tamara Intermesoli, Margherita Maffioli, Chiara Elena, Alessandro Melosi, Federico Simonetti, Enrico Capochiani, Roberta Della Seta, Matteo Pacilli, Mario Luppi, Nicola Di Renzo, Lucia Mastrullo, Elena Trabacchi, Daniele Vallisa, Davide Rapezzi, Ester Maria Orlandi, Carlo Gambacorti-Passerini, Fabio Efficace & Giuliana Alimena. (2016) Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis. Supportive Care in Cancer 24:11, pages 4487-4493.
Crossref
Melea A. Ward, Gang Fang, Gang Fang, Kristy L. Richards & Christine M. Walko. (2015) Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia. Journal of Health Economics and Outcomes Research 2:2, pages 181-191.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.